Hence, the synergy between enzalutamide and USP14 inhibition in antitumor effect on breast cancer also may be attributable to additional tumor suppressing actions from USP14 inhibition, beyond suppressing AR signaling. The gene discussed is USP14; the disease is neoplasm.